Ratnoff O D, Kass L, Lang P D
J Clin Invest. 1969 May;48(5):957-62. doi: 10.1172/JCI106055.
A high degree of purification of antihemophilic factor was achieved by filtration of chylomicronpoor human plasma through columns of agarose. The final product contained, on the average, 67 units of antihemophilic activity per mg of protein, and was 3360-fold purified compared with the filtered plasma. The molecular weight of antihemophilic factor appeared to be at least two million. Preparations separated by gel filtration were contaminated with appreciable amounts of plasma thromboplastin antecedent (PTA), and traces of Christmas factor and Hageman factor, but no detectable fibrinogen was present. Similar fractions of plasma prepared from the blood of patients with classic hemophilia, von Willebrand's disease, or a circulating anticoagulant directed against antihemophilic factor contained, on the average, somewhat less protein than normal plasma; whether this difference was significant is not yet known. The purified fractions were partially stabilized by the addition of 1% gelatin. Adaptation of the technique of gel filtration to purification of antihemophilic factor for clinical use remains to be explored.
通过将去乳糜微粒的人血浆通过琼脂糖柱过滤,实现了抗血友病因子的高度纯化。最终产物平均每毫克蛋白质含有67单位的抗血友病活性,与过滤后的血浆相比纯化了3360倍。抗血友病因子的分子量似乎至少为两百万。通过凝胶过滤分离的制剂被相当数量的血浆促凝血酶原激酶前体(PTA)以及微量的克里斯马斯因子和哈格曼因子污染,但未检测到纤维蛋白原。从典型血友病、血管性血友病或针对抗血友病因子的循环抗凝剂患者血液中制备的类似血浆部分,平均而言,蛋白质含量略低于正常血浆;这种差异是否显著尚不清楚。通过添加1%明胶,纯化后的部分得到了部分稳定。凝胶过滤技术在临床使用中用于纯化抗血友病因子的适应性仍有待探索。